Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection

Sara Lodi1*, Martin Fisher2, Andrew Phillips3, Andrea De Luca4, Jade Ghosn5, Rusan Malyluta6, Robert Zangerle7, Santiago Moreno8, Philippe Vanhems9, Faroudy Boufassa10, Marguerite Guiguet11, Khouloud Porter12, for CASCADE Collaboration in EuroCoord1

1 Instituto de Salud Carlos III, Madrid, Spain, 2 Brighton and Sussex University Hospitals National Health Service Trust, Brighton, United Kingdom, 3 University College of London, London, United Kingdom, 4 University Division of Infectious Diseases, University Hospital of Siena, Siena, Italy, 5 Universite Paris Descartes, EA 3620, Paris, France, 6 Perinatal Prevention of AIDS Initiative, Odessa, The Ukraine, 7 Innbruck Medical University, Innbruck, Austria, 8 Hospital Ramon y Cajal, Madrid, Spain, 9 Edouard Herriot Hospital, Lyon, and Universite de Lyon 1, Lyon, France, 10 INSERM and UPMC Univ Paris 06, UMR S 943, Paris, France, 12 MRC Clinical Trials Unit at University College London, London, United Kingdom

Abstract

Background: The risk/benefit of initiating ART in primary HIV infection (PHI) is unclear. The benefits are more likely to outweigh the risks in patients with severe PHI. An accepted definition of severe PHI is, however, lacking.

Methods: CASCADE patients with HIV test interval <6 months were classified as severe and non-severe PHI based on whether the following traits were recorded in the first 6 months following seroconversion: severe specific pre-defined symptoms, central nervous system-implicated illness, and ≥1, ≥2 CD4 <350 (and <500) cells/mm³. For each definition, we used Kaplan-Meier curves and Cox survival models to compare time to AIDS/death, censoring at the earlier of last clinic visit or 1/1/1997, when combination antiretroviral therapy (cART) became available.

Results: Among 1108 included patients mostly males (85%) infected through sex between men (71%), 366 were diagnosed with AIDS/died. The risk of AIDS/death was significantly higher for individuals with severe symptoms, those with ≥1 CD4 <350 cells/mm³ or ≥2 CD4 <500 cells/mm³ in the first 6 months [aHR (95% confidence interval) 2.1 (1.4,3.2), 2.0 (1.5–2.7), and 2.3, (1.5–3.5) respectively]. Median [interquantile range] survival for patients with ≥2, ≥1 and no CD4 <350 cells/mm³ within 6 months of seroconversion was 3.9 [2.7,6.5], 5.4 [4.5,8.4] and 8.1 [4.3,10.3] years, respectively. The diagnosis of CNS-implicated symptoms was rare and did not appear to be prognostic.

Conclusion: One CD4 count <350 or two <500 cells/mm³ within 6 months of seroconversion and/or severe illness in PHI may be useful early indicators of individuals at high risk of disease progression.

Background

Although the virological and clinical features of primary HIV infection (PHI) were described nearly 20 years ago [1,2], it has not been clearly established whether and what characteristics of that early phase are predictive of subsequent faster HIV disease progression. The risk/benefit trade-off of initiating ART in PHI is unclear but the benefits are more likely to outweigh the risks in patients with severe PHI. However, an accepted definition of severe PHI, based on clinical, virological and/or immunological characteristics during that initial period, is lacking.

Several studies have suggested that presence of seroconversion illness with long-lasting symptoms is associated with poorer subsequent outcomes [3,4,5]. As some symptoms are more severe than others with symptoms ranging from a simple flu-like
symptoms to aseptic meningitis [6], the illness itself and its intensity may be predictive of disease progression. In particular, symptoms which signify the involvement of the central nervous system (CNS), such as meningoencephalitis, are known to be life-threatening, as demonstrated by a recent case of fatal brain necrosis in PHI [7].

Results from observational studies on the predictive value of immunological and virological markers in early HIV infection are inconsistent. Although it has been shown that low levels of CD4 cell count in early HIV infection are predictive of faster disease progression [8,9,10], to our knowledge no study has provided a practical definition of what CD4 cell level should be considered as low.

US guidelines for antiretroviral treatment in HIV positive patients indicate cART as optional for patients with ongoing PHI and for those known to have seroconverted in the past 6 months, while European guidelines indicate optional treatment for patients with severe seroconversion illness, although a definition of severity is not provided [11,12]. The optimal management of patients diagnosed during PHI, however, remains unresolved. We have, therefore, used data from routine clinical practice of patients diagnosed with HIV during, or shortly after HIV seroconversion, to explore definitions of PHI severity based on clinical and immunological features in the first 6 months following HIV seroconversion before the initiation of cART.

Methods

Patients

We used data from CASCADE in EuroCoord (www.EuroCoord.net), a collaboration of cohorts of patients with well-estimated dates of HIV seroconversion in Europe, Australia, Canada, and sub-Saharan Africa [13]. The data for this study were pooled in 2006 and, unlike most recent updates, included information on reported seroconversion illness and specific symptoms. The date of HIV seroconversion, used to approximate the date of HIV infection, was estimated by various methods: most frequently as the midpoint between dates of the last negative and first positive HIV antibody test results, the date of laboratory evidence of seroconversion or the date of a seroconversion illness (and an earlier documented negative HIV test result). For this study we restricted to patients with laboratory evidence of seroconversion or an HIV test interval ≤6 months. Patients enrolled in cohorts not reporting information on seroconversion illness and/or with an estimated date of HIV seroconversion after 31/12/1996, when combination antiretroviral therapy (cART) became available, were excluded.

Ethics statement

All cohorts in CASCADE received approval from their individual ethics review boards. Approval was also given by all ethics review boards to pool anonymised data for analyses and dissemination (see Appendix S1). Signed informed consent was obtained from all patients.

Definitions of severe primary HIV infection

We explored the following definitions for PHI severity based on clinical characteristics and CD4 measurements within 6 months of HIV diagnosis, i.e. from the first test confirming HIV infection or laboratory evidence of seroconversion, by considering each definition in turn and assigning eligible individuals to whether or not they have the respective trait:

i) clinical - severe illness.: symptomatic seroconversion which included at least one of the following disorders judged to be severe a priori by a panel of physicians [MF, ADL, RZ SM personal communication]: bronchitis, pneumonia, oral candidiasis, thrombocytopenia, viral meningitis, bacterial meningitis, encephalitis, neuropathy, candida pharyngitis

ii) clinical - CNS involvement.: symptomatic seroconversion which included at least one of the following disorders indicating neurological involvement agreed by the same panel of physicians: viral meningitis, bacterial meningitis, encephalitis, neuropathy

iii) immunological - CD4 count <350 cells/mm³.: at least one, then at least two CD4 counts <350 cells/mm³ within 6 months of HIV seroconversion

iv) immunological - CD4 count <500 cells/mm³.: at least one, then at least two CD4 counts <500 cells/mm³ within 6 months of HIV seroconversion

v) combinations of clinical and immunological definitions.: severe illness/illness with CNS involvement and at least one CD4 count <350/<500 cells/mm³ within 6 months of HIV seroconversion.

Analyses assessing the predictive value of immunological definitions requiring two CD4 cell count measurements were restricted to patients who had at least two CD4 counts measured within 6 months of HIV diagnosis. The cut-points for the immunological definitions were chosen based on current guidelines for treatment initiation in chronic infection [11,12].

Statistical analyses

For each of the above definitions, Kaplan-Meier methods were used to compare time to the earlier of AIDS or death for patients with and without each trait. Follow-up was right-censored at the earlier of the last clinic visit or, to avoid selective censoring due to cART initiation in patients with worse prognosis, 31/12/1996.

For each definition, Cox semi-parametric regression models were used to assess the association between each trait and risk of AIDS/death while adjusting for the following potential confounders: sex, age at HIV seroconversion and risk group. For the clinical definitions, we also adjusted for the first recorded CD4 cell count after seroconversion. Potential confounders were defined as a priori variables known to be associated with both the specific trait and HIV disease progression, but which are not on the causal pathway. Fractional polynomial models were also fitted to explore the relationship between CD4 cell count predictors and risk of death/AIDS [14]. There was a non-linear age effect on survival and two age groups based on median age at seroconversion (<30 and ≥30 years) were, therefore, used. All models allowed for late entry into the risk set at the time the patient was enrolled into the constituent cohort to minimise survivorship bias. AIDS was defined using the European case definition, i.e. excluding a CD4 count <200 cells/mm³ [15]. The prognostic importance of each trait was assessed using Wald tests from the adjusted models and the R² index of explained variation for censored data taking values between 0 and 1 with a higher R² score indicating a stronger association [16]. Statistical analyses were performed with Stata 12.

Sensitivity analyses

As CD4 count is known to drop transiently at the time of HIV seroconversion, analyses of immunological definitions were also conducted excluding all CD4 counts collected within 4 weeks of the estimated date of seroconversion. Moreover, since patients with missing information on seroconversion illness symptoms or
CD4 count within 6 months of HIV diagnosis were excluded from the analyses of the clinical and immunological definitions and this missing data mechanism may not be completely at random, we repeated the analyses imputing the trait for those with missing values [17].

**Results**

**Patients**

Of the 17146 patients in CASCADE, 1108 were included in the analyses while the remaining patients were excluded as follows: 11083 had an HIV test interval >6 months, 2362 seroconverted after 31/12/1996, 2593 were enrolled in cohorts not reporting information on seroconversion illness. The included patients were mostly males (85%), infected through sex between men (71%) with median [interquartile range (IQR)] first CD4 count of 511 [350,700] cells/mm³ recorded after 3.5 months [1.7,14.1] after seroconversion and median age at seroconversion of 29 years [24,35] (Table 1). Clinical progression occurred in 366 patients of whom 326 developed AIDS and 40 died during 4965.6 person-years (PY) of follow-up (incidence rate of AIDS/death 7.4/100 PY). Median [IQR] AIDS-free survival time was 8.0 [4.6,14.0] years. As shown in Table 1, the characteristics of patients included in the clinical and immunological definition analyses were similar to those of the overall eligible patient population. Patients with $\geq 1$ CD4 count had a median [IQR] of 2 [1,3] CD4 measurements in the first 6 months after HIV diagnosis per patient and a median time from HIV seroconversion to first recorded CD4 count of 2.3 months [0.8,3.7].

**Clinical definitions**

Among 865 patients with information on seroconversion illness, 127 (15%) reported severe symptomatic illness, with Candida pharyngitis (35 cases), oral candidiasis (32), pneumonia (24), bronchitis (23) and viral meningitis (21) being the most common illnesses. Among the 738 patients without severe symptoms, 51% reported a seroconversion illness and the remainder reported no illness. Median [IQR] survival for patients with severe symptoms was 6.3[3.7,-], shorter than the 8.3 [4.8,14.0] years experienced by the remainder ($p = 0.003$, log-rank test). After adjustment for potential confounders, patients with severe illness experienced a hazard of AIDS/death of 2.1 (95% CI 1.4,3.2) compared to those without severe illness (Table 2).

Seroconversion illness with CNS involvement (21, 19 and 1 cases of viral meningitis, neuropathy and encephalitis, respectively) was reported in 32 patients (3.7%). There was no significant difference in survival between those with and without this trait in univariate or adjusted analyses (Table 2). Among those with and without the trait, 3 (9.4%) and 54 (6.5%) patients, respectively, developed an AIDS event with neurological involvement (dementia, encephalitis, toxoplasmosis or cerebral lymphoma) ($p = 0.518$, Pearson $\chi^2$ test).

**Immunological definitions**

Figure 1 represents the risk of disease progression among 740 patients with $\geq 1$ CD4 count in 6 months of HIV diagnosis as a function of the lowest recorded CD4 count in the first 6 months of HIV diagnosis. The risk of disease progression increased as the lowest CD4 count measured in the first 6 months decreased with a very marked increase in risk for individuals with at least one CD4 count $<100$ cells/mm³.

| Table 1. Characteristics of included patients overall and separately for clinical and immunological definitions of severe primary HIV infection (PHI). |
|------------------|------------------|------------------|
|                  | Overall          | Clinical definition (known SC illness status) | Immunological definition (\(\geq 1\) CD4 count within 6 months of HIV SC) |
| N                | 1108             | 865              | 740              |
| Risk category    |                  |                  |                  |
| Sex between men  | 789 [71%]        | 633 [73%]        | 543 [73%]        |
| Injecting drug use| 132 [12%]        | 73 [8%]          | 34 [9%]          |
| Sex between men & women | 154 [14%] | 126 [15%] | 105 [14%] |
| Other/unknown    | 33 [3%]          | 33 [3%]          | 28 [4%]          |
| Sex              |                  |                  |                  |
| Female           | 166 [15%]        | 121 [14%]        | 97 [13%]         |
| Age at SC        |                  |                  |                  |
| Median [IQR], years | 29 [24,35]     | 30 [25,36]       | 30 [25,36]       |
| Time first CD4 after SC | 3.5 [1.7,14.1] | 3.3 [1.4,11.8]  | 2.4 [0.8,3.7]   |
| First CD4 after SC | 511 [350,700]  | 522 [354,702]   | 556 [390,740]   |
| HIV test interval |                  |                  |                  |
| Median [IQR], days | 88 [24,135]    | 82 [15,132]      | 76 [14,126]      |
| Year of SC       |                  |                  |                  |
| Median [IQR], calendar year | 1991 [1988,1994] | 1991 [1988,1994] | 1992 [1989,1994] |

Abbreviations: SC = seroconversion, IQR = Interquartile range.

*doi:10.1371/journal.pone.0078642.t001*
| Clinical definition- severe illness * | N | Person-year follow-up | Events | Median [IQR] survival time, years | P-value - unadjusted model ¥ | Hazard ratio (95% CI) | P-value - adjusted from Cox model | R² (95% CI) |
|-------------------------------------|---|-----------------------|--------|----------------------------------|-----------------------------|-----------------------|----------------------------------|------------|
| Yes                                 | 127 | 425.1                | 41     | 6.3 [3.7, -]                     | 0.003                       | 2.2 (1.4,3.2)*         | <0.001                           | 0.11 (0.06, 0.20) |
| No                                  | 738 | 3483.1               | 243    | 8.3 [48,13.9]                    |                             | 1                     |                                  |            |
| Clinical definition- CNS involvement * | Yes | 32 | 120.1 | 8 | - [3.9, -] | 0.943 | 1.0 (0.5,2.2)* | 0.932 | 0.09 (0.05,0.19) |
| N                                   | 833 | 3788.1               | 276    | 8.2 [46,14.0]                    |                             | 1                     |                                  |            |
| Immunological definition- CD4 <350 cells/mm³ | Yes | 207 | 680.4 | 82 | 5.1 [34,7.9] | <0.001 | 2.0 (1.5,2.7)* | <0.001 | 0.10 (0.05,0.19) |
| No                                  | 533 | 2171.3               | 139    | 8.7 [48, 11.5]                   |                             | 1                     |                                  |            |
| Immunological definition- CD4 <500 cells/mm³ | Yes | 399 | 1432.5 | 152 | 5.5 [38,9.1] | <0.001 | 2.2 (1.6,3.0)* | <0.001 | 0.11 (0.06,0.22) |
| No                                  | 341 | 1419.2               | 69     | 10 [5, -]                       |                             | 1                     |                                  |            |
| Immunological definition- 2 CD4 <350 cells/mm³ ◊ | No CD4 count <350 | 282 | 1005.4 | 77 | 8.1 [43,10.6] | <0.001 | 1 | <0.001 | 0.08 (0.03,0.22) |
| One CD4 <350                        | 73  | 260.9                | 26     | 5.4 [45,8.4]                    | 1.4 (0.9,2.2)               | 1.4 (0.9,2.2)          | 0.08 (0.03,0.22)               |
| 2 or more CD4 <350                  | 88  | 246.0                | 38     | 3.9 [27,6.5]                    | 2.5 (1.6,3.9)               | 2.5 (1.6,3.9)          | 0.08 (0.03,0.22)               |
| Immunological definition- 2 CD4 <500 cells/mm³ ◊ | No CD4 count <500 | 159 | 520.4 | 31 | 7.5 [47,10.0] | <0.001 | 1 | <0.001 | 0.09 (0.04,0.23) |
| One CD4 <500                        | 95  | 390.9                | 32     | 6.7 [49,10.6]                   | 1.1 (0.7,1.9)               | 1.1 (0.7,1.9)          | 0.09 (0.04,0.23)               |
| 2 or more CD4 <500                  | 189 | 601.0                | 78     | 4.8 [30,8.4]                    | 2.3 (1.5,3.5)               | 2.3 (1.5,3.5)          | 0.09 (0.04,0.23)               |

* = bronchitis, pneumonia, oral candidiasis, thrombocytopenia, viral meningitis, bacterial meningitis, encephalitis, neuropathy, Candida pharyngitis.

* Μ = viral meningitis, bacterial meningitis, encephalitis, neuropathy.

* Α = Adjusted for sex, risk group (sex between men, injecting drug use, sex between men and women, other/unknown), age at HIV seroconversion (<30 and ≥30 years) and first CD4 count (<350, 351–500 and ≥500 cells/mm³).

* Β = Adjusted for sex, risk group (sex between men, injecting drug use, sex between men and women, other/unknown), age at HIV seroconversion (<30 and ≥30 years).

* Σ = Long rank test for difference in survivor probabilities.

* Χ = Cox semiparametric survival model.

* Ψ = Heterogeneity test for categorical variables.

* Χ = The symbol '-' for median survival time indicates that fewer than 50% of patients at risk have experienced the event by the end of follow-up.

* Ψ = Analyses only included patients with at least 2 CD4 counts measured in the first 6 months of HIV diagnosis.

doi:10.1371/journal.pone.0078642.t002

Table 2. Risk of AIDS and/or death according to definition of severe primary HIV infection (PHI).
Among 740 patients with \( \geq 1 \) CD4 count in 6 months of HIV diagnosis, 207 (28%) and 399 (54%) patients experienced \( \geq 1 \) CD4 count, 350 and \( \geq 1 \) CD4 count, 500 cells/mm\(^3\), respectively. There was strong evidence of a survival difference between those with and without such a CD4 value for both immunological definitions (\( p < 0.001 \)) in univariable and adjusted analyses (Table 2). The adjusted hazard ratios for those with \( \geq 1 \) CD4 count <350 and \( \geq 1 \) CD4 count <500 cells/mm\(^3\) were 2.0 (95% CI 1.5, 2.7) and 2.2 (1.6, 3.0), respectively. The \( R^2 \) for the adjusted models for the two definitions suggested that the included covariates explained 10% and 11% of the total variability in clinical progression (Table 2).

443 patients had at least 2 CD4 measurements within 6 months of the HIV diagnosis (180, 263 with two, and three or more measurements, respectively). There was strong evidence of difference in survival for patients with none (\( n = 282 \)), 1 (\( n = 73 \)) and \( \geq 2 \) CD4, 350 cells/mm\(^3\) within 6 months of HIV diagnosis with median IQR survival times of 8.1 [4.3,10.6], 5.4 [4.5,8.4] and 3.9 [2.7,6.5], respectively (\( p < 0.001 \) log-rank test). Similarly, patients with no, 1 and \( \geq 2 \) CD4, 500 cells/mm\(^3\) had median survival times of 7.3 [4.7,10.0], 6.7 [4.9,10.6] and 4.8 [3.0,8.4] years (\( p < 0.001 \)) and proportion alive and AIDS-free at 4 years of HIV seroconversion of 86% (95%CI 77%,92%), 80% (67%,89%) and 60% (30%,68%), respectively.

Combination of clinical and immunological definitions

Of 604 patients with known seroconversion illness status and at least one CD4 count recorded within 6 months of HIV diagnosis, 31 patients had a severe seroconversion illness and at least one CD4 count <350 cells/mm\(^3\). Such individuals were at increased risk of AIDS/death (HR = 2.0, 1.0–3.8) compared to those with a CD4 count <350 alone (Table 3). Similarly, patients with a severe seroconversion illness and at least one CD4 count <500 cells/mm\(^3\) experienced 2.2 (1.3,3.6) times the hazard of clinical progression of patients with a severe illness alone. There was no significant difference in survival between patients with a seroconversion illness with CNS involvement and at least one CD4 count <500 cells/mm\(^3\) or at least one CD4 count <350 cells/mm\(^3\) (Table 3).

Sensitivity analyses

Excluding CD4 counts in the first 4 weeks of HIV seroconversion or imputing PHI severity status when this was missing did not materially change the results of the analyses (results not shown).

Discussion

In this large study of patients diagnosed in PHI, we found that patients experiencing any of the following within 6 months of HIV diagnosis were more likely to experience more rapid progression of disease: one CD4 count <350 cells/mm\(^3\), 2 CD4 counts <500 cells/mm\(^3\), and/or experience of severe seroconversion illness (any of bronchitis, pneumonia, oral or pharyngeal candidiasis, thrombocytopenia, viral meningitis, bacterial meningitis, encephalitis, neuropathy). We found that seroconversion illness with CNS involvement (ie, viral meningitis, bacterial meningitis, encephalitis, and neuropathy) was rare and there was no statistical evidence to suggest that this associated increased risk of AIDS/death, although confidence intervals were wide.

Our regression models for each definition of severe PHI only explained between 9 and 12% of variability in survival following seroconversion. Thus, these should not be interpreted as prognostic models, since other factors in primary and chronic HIV infection, many of which are unknown, account for the remaining variation. They suggest, however, that in a considerable proportion of patients infected with HIV, progression of HIV disease may already be determined in early infection.

We found that 54% and 28% of patients diagnosed in PHI had at least one CD4 count <500 and <350 cells/mm\(^3\) measured in the first 6 months, respectively. This is consistent with our previous findings that low CD4 counts are not uncommon in PHI [18]. This study also suggests that early CD4 counts below these levels,
Table 3. Risk of AIDS and/or death according to combinations of clinical and immunological definitions of severe PHI.

|                               | N   | Person-year follow-up | Events | Median [IQR] survival time, years | P-value - unadjusted model | Hazard ratio (95% CI) | P-value - adjusted from Cox model | R2 (95% CI) |
|-------------------------------|-----|-----------------------|--------|----------------------------------|---------------------------|----------------------|----------------------------------|-------------|
| **Severe symptoms and/or CD4 < 350 cells/mm³** |     |                       |        |                                  |                           |                      |                                  |             |
| Neither                       | 374 | 1666.3                | 100    | 8.9 [5.0,11.5]                  | <0.001                    | 0.5 [0.3,0.7]        | <0.001                          | 0.11 [0.07,0.23] |
| CD4 < 350 alone               | 140 | 485.1                 | 57     | 4.9 [3.7,7.9]                   |                           | 1                    |                                  |             |
| Severe symptoms alone         | 59  | 193.7                 | 19     | 5.8 [4.1,9.3]                   |                           | 1.0 [0.6,1.8]        |                                  |             |
| Both                          | 31  | 88.0                  | 13     | 4.9 [1.4, -]                    |                           | 2.0 [1.0,3.8]        |                                  |             |
| **Severe symptoms and/or CD4 < 500 cells/mm³** |     |                       |        |                                  |                           |                      |                                  |             |
| Neither                       | 244 | 1107.1                | 55     | 10.0 [5.4, -]                   | <0.001                    | 0.5 [0.3,0.7]        | <0.001                          | 0.11 [0.06,0.22] |
| CD4 < 500 alone               | 270 | 1044.3                | 102    | 6.0 [3.9,9.3]                   |                           | 1                    |                                  |             |
| Severe symptoms alone         | 33  | 100.0                 | 5      | - [43, -]                       |                           | 1.0 [0.3,1.7]        |                                  |             |
| Both                          | 57  | 181.6                 | 27     | 5.4 [2.8,6.3]                   |                           | 2.2 [1.3,3.6]        |                                  |             |
| **CNS involvement and/or CD4 < 350 cells/mm³** |     |                       |        |                                  |                           |                      |                                  |             |
| Neither                       | 413 | 1787.8                | 116    | 8.7 [4.9,11.5]                  | <0.001                    | 0.5 [0.3,0.7]        | <0.001                          | 0.09 [0.05,0.30] |
| CD4 < 350 alone               | 164 | 551.2                 | 66     | 5.1 [3.6,7.9]                   |                           | 1                    |                                  |             |
| CNS involvement alone         | 20  | 72.3                  | 3      | - [-,-]                         |                           | 0.4 [0.1,1.2]        |                                  |             |
| Both                          | 7   | 218.8                 | 4      | 3.9 [3.4,4.9]                   |                           | 1.9 [0.7,5.5]        |                                  |             |
| **CNS involvement and/or CD4 < 500 cells/mm³** |     |                       |        |                                  |                           |                      |                                  |             |
| Neither                       | 265 | 1157.9                | 60     | 10.0 [5.4, -]                   | <0.001                    | 0.5 [0.3,0.7]        | <0.001                          | 012 [0.7,2.23] |
| CD4 < 500 alone               | 312 | 1181.1                | 122    | 5.7 [3.9,9.3]                   |                           | 1                    |                                  |             |
| CNS involvement alone         | 12  | 49.3                  | 0      | - [-,-]                         |                           | -                    |                                  |             |
| Both                          | 15  | 44.8                  | 7      | 3.9 [2.8,4.9]                   |                           | 1.9 [0.9,4.5]        |                                  |             |

- * bronchitis, pneumonia, oral candidiasis, thrombocytopenia, viral meningitis, bacterial meningitis, encephalitis, neuropathy, Candida pharyngitis.
- °viral meningitis, bacterial meningitis, encephalitis, neuropathy.
- !Adjusted for sex, risk group (sex between men, injecting drug use, sex between men and women, other/unknown), age at HIV seroconversion (<30 and >30 years) and first CD4 count (<350, 351–500 and >500 cells/mm³).
- !Adjusted for sex, risk group (sex between men, injecting drug use, sex between men and women, other/unknown), age at HIV seroconversion (<30 and >30 years).
- ¥Long rank test for difference in survivor probabilities.
- ¥Heterogeneity test for categorical variables.
- ¥Cox semiparametric survival model.
- ¥The symbol "-" for median survival time indicates that fewer than 50% of patients at risk have experienced the event by the end of follow-up.
- ¥doi:10.1371/journal.pone.0078642.t003

*Adjusted for sex, risk group (sex between men, injecting drug use, sex between men and women, other/unknown), age at HIV seroconversion (<30 and >30 years) and first CD4 count (<350, 351–500 and >500 cells/mm³).
especially when recorded more than once, are predictive of fast disease progression. In particular, we found that having 2 CD4<500 cells/mm$^3$ in the first 6 months of HIV diagnosis was associated with a probability of being alive and AIDS-free at 4 years of HIV seroconversion of 60% (95% CI 50%-80%), lower than the estimated 86% (77%-92%) for individuals without a CD4<500 cells/mm$^3$ at that time. This underlines that immunological status can rapidly deteriorate in the first months following seroconversion in the absence of antiretroviral therapy.

HIV penetrates the CNS very early following infection and severe CNS symptoms have been reported in that period [7,19]. It has been postulated that neurological involvement at PHI could be an indicator for poor prognosis and subsequent irreversible neurological disease [20,21]. In our study there was no statistical effect of neurological involvement in PHI on clinical progression of HIV disease and the risk of CNS AIDS events for patients with and without seroconversion illness with CNS involvement was similar. Nevertheless, since the number of patients with seroconversion illness with CNS involvement was small (32 cases), we may have missed a significant effect of this definition of PHI severity.

The prognostic value of HIV-RNA in the first 6 months following seroconversion is controversial and results have shown discrepant conclusion. Whereas the prognostic value of elevated levels of set-point HIV RNA is well established [22,23], study investigators have reached discordant conclusions on the predictive value of HIV-RNA levels at the time of seroconversion [2,8,9,24,25,26]. Among immunological parameters, low CD8 cell count in early HIV infection have been shown to be correlated with faster disease progression [27,28]. Unfortunately, we only had limited HIV-RNA data as HIV-RNA in the pre-cART era was not monitored routinely and CD8 cell count is not collected in CASCADE. We were, thus, unable to explore the effect of these markers further. Nevertheless, the advantage of our classification based on clinical and CD4 count in early HIV infection is its relatively simplicity and potential for use in resource limited settings where laboratory infrastructures are lacking.

Our analyses were subject to several important limitations. First, initial studies suggested that long lasting and intense symptoms during PHI are associated with poorer prognosis [3,4,5]. It is possible that a better definition of PHI severity would include also number and duration of seroconversion symptoms. As we had no information on the intensity and duration of symptoms we could not explore their predictive values on risk of clinical progression.

Second, reporting of seroconversion illness is subject to recall bias at the time of the HIV-positive test as seroconversion illnesses are more likely to be reported by patients with worst initial prognosis [6]. This would lead to an overestimation of the effect of seroconversion illness on the risk of progression. Nevertheless, we believe that our estimates are unlikely to be affected by self report bias, since severe seroconversion illnesses as defined in this study consisted of clinical symptoms likely to be well-documented in patient records.

Finally, we used data collected in the pre-cART era to avoid selective drop at cART initiation for patients with worse prognosis. Recent studies have reported lower initial CD4 cell counts in individuals who have seroconverted more recently [29] and faster disease progression [30]. It is possible, therefore, that our conclusions about the predictive value of clinical and immunological characteristics are not generalized to more recently-infected individuals.

Initiation of cART in PHI could be beneficial to prevent rapid progression in patients with severe PHI. The best practice for the clinical management of patients diagnosed in PHI or early HIV infection remains unknown and there is ongoing debate on the value, timing and optimal duration of cART in PHI. In three recent randomised controlled trials (RCTs) patients who received transient cART in PHI presented longer times to CD4<350 cells/mm$^3$, lower viral set-point or delayed initiation of cART according to recommendations for chronic infection [31,32,33] compared with patients who did not receive cART in PHI. Nevertheless, because of the limited follow-up, these trials were unable to answer questions on the beneficial effect of transient early cART in altering long-term disease progression. Moreover, treatment duration in these studies was relatively short, ranging from 12-60 weeks and it is possible that longer durations of transient cART could be more beneficial. No study has examined whether cART initiated in PHI should be continued long-term. The European guidelines recommend that once it is initiated, treatment in PHI should be lifelong [12]. Nevertheless, there is no strong scientific basis to support this statement and unlike treatment in chronic infection, discontinuation of transient cART in PHI has been shown not to be associated with increased HIV morbidity and increases in inflammatory and coagulation markers [34]. Until consensus on the benefit and administration of treatment in PHI is reached, these criteria could be helpful early indicators to identify individuals at risk of rapid HIV disease progression.

In conclusion, this study suggests that one or more CD4<350 cells/mm$^3$ and/or severe clinical seroconversion illness, may be a useful indicator for identifying patients who are likely to benefit from early treatment and initial close monitoring. More evidence from RCT is needed to establish the beneficial value of treatment initiation in PHI.

Supporting Information

Appendix S1 The CASCADE collaboration in Euro-Coord. (DOCX)

Acknowledgments

CASCADE Collaborators: Australia PHAE-DRA cohort (Tony Kelleher, David Cooper, Pat Grey, Robert Finlayson, Mark Bloch) Sydney AIDS Prospective Study and Sydney Primary HIV Infection cohort (Tony Kelleher, Tim Ramacciotti, Linda Gelgor, David Cooper, Don Smith); Austria Austrian HIV Cohort Study [Robert Zangerle]; Canada South Alberta clinic (John Gill); Estonia Tartu Ulkool (Ira Lastar); France ANRS CO3 Aquitaine cohort (Geneviève Chène, François Dahis, Rodolphe Thiebaut, Bernard Masquelier), ANRS CO4 French Hospital Database (Dominique Costagliola, Marguerite Guiguet), Lyon Primary Infection cohort (Philippe Vanhems), French ANRS CO6 PRIMO cohort (Marie-Laure Chaux, Jade Ghosn), ANRS CO9 SEROCO cohort (Laurence Meyer, Farouky Boufassa); Germany German HIV-1 seroconverter cohort (Osamah Hamoudeu, Claudia Kücherer, Barbara Bartmeyer); Greece AMACS (Anastasia Antoniadou, Georgios Chrysos, Georgios L. Daikos); Greek Haemophilia cohort (Giota Toulioumi, Nikos Pantazis, Olga Katsarou); Italy Italian Seroconversion Study (Giovanni Rezza, Maria Dorracco), ICONA cohort (Antonella d’Arminio Monforte, Andrea De Luca.) Netherlands Amsterdam Cohort Studies among homosexual men and drug users (Maria Prins, Ronald Geskus, Jannie van der Helm, Hanneke Schuitemaker); Norway Oslo and Ulleval Hospital cohorts (Mette Sannes, Oddbjorn Brubakk, Anne-Marte Bakken Kran); Poland National Institute of Hygiene (Magdalena Rosinska); Spain Badalona IDU hospital cohort (Roberto Muga, Jordi Tor), Barcelona IDU Cohort (Patricia García de Olalla, Joan Cayla), CoRIS-cv (Julia del Arno, Santiago Moreno, Susana Mouy), Madrid cohort (Julia Del Arno, Jorge del Romero), Valencia IDU cohort (Santiago Perez-Hoyos); Switzerland Swiss HIV Cohort Study (Heiner C. Bucher, Martin Rickenbach, Patrick Francioli); Ukraine Perinatal Prevention of AIDS Initiative (Ruslan Maluta); United Kingdom Health Protection Agency (Gary Murphy), Royal Free haemophilia cohort (Caroline Sahin), UK Register of HIV Seroconverters (Kholoud Porter, Anne Johnson, Andrew Phillips, Abdel
Author Contributions
Conceived and designed the experiments: SL MF KP. Wrote the paper: SL KP. Analysis and interpretation: SL MF AP ADL JG RM SM PV FB MG KP. Obtained funding: KP. Statistical analyses: SL.

References
1. Cooper DA, Gold J, Maclean P, Donovan B, Finlayson R, et al. (1985) Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1: 537–540.
2. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L (1998) Biological and virologic characteristics of primary HIV infection. Ann Intern Med 128: 613–620.
3. Pedersen C, Lindhardt BO, Jensen BL, Lauritzen E, Gerstoft J, et al. (1989) Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 299: 154–157.
4. Lindback S, Brostrom C, Karlsson A, Gaines H (1994) Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10^6/l, AIDS, and death from AIDS? BMJ 309: 1353–1357.
5. Vanheems P, Lambert J, Cooper DA, Perrin L, Carr A, et al. (1998) Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 26: 323–329.
6. CASCADE European Collaborative Project (2001) The relationships between the HIV test interval, demographic factors and HIV disease progression. Epidemiol Infect 127: 91–100.
7. Meerensen W, Van Laethem K, Lagrou K, Wilms G, Sciot R, et al. (2005) Fatal brain necrosis in primary HIV infection. Lancet 366: 866.
8. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, et al. (2006) CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 42: 709–713.
9. Ghosn J, Deveau C, Chaix ML, Goujard C, Galimand J, et al. (2010) Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother 65: 741–748.
10. Buchacz K, Hu DJ, Vanichseni S, Mock PA, Chaowasunanthan T, et al. (2004) Early markers of HIV-1 disease progression in a prospective cohort of seroconverters in Bangkok, Thailand: implications for vaccine trials. J Acquir Immune Defic Syndr 36: 853–860.
11. Panel on antiretroviral guidelines for adults and adolescents(2012) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. In: Department of Health and Human Services, editor.
12. European AIDS clinical society (EACS) (2012) European guidelines for treatment of HIV infected adults in Europe.
13. Wolbers M, Bahiker A, Sahin C, Young J, Dorracci M, et al. (2010) Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy: the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med 7: e1000239.
14. Royston P, Ambler G, Sauerbrei W (1999) The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 28: 964–974.
15. Ancelle-Park R (1993) Expanded European AIDS case definition. Lancet 341: 441.
16. Royston P (2006) Explained variation for survival models. Stata Journat 6: 83–96.
17. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, et al. (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338: b2393.
18. Lodi S, Phillips A, Touloumi G, Gusku R, Meyer L, et al. (2011) Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm3: assessment of need following changes in treatment guidelines. Clin Infect Dis 53: 817–825.
19. Jones HR Jr, Ho DD, Forcades P, Adelman LS, Silverman ML, et al. (1988) Acute fulminating fatal leukoencephalopathy as the only manifestation of human immunodeficiency virus infection. Ann Neurol 23: 519–522.
20. Dounyoviamnis M, Litman N (2009) Acute encephalopathy and multi-organ involvement with rhabdomyolysis during primary HIV infection. Int J Infect Dis 13: e299–304.
21. Bouloufa F, Bachmeyer C, Case R, Deveaux C, Perrouz A, et al. (1995) Influence of neurologic manifestations of primary human immunodeficiency virus infection on disease progression. SEROCO Study Group. J Infect Dis 171: 1190–1195.
22. Mellors JW, Munoz A, Giorgi JV, Marzukick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946–954.
23. Lavreys L, Baeten JM, Chohan V, McClelland RS, Hassan WM, et al. (2006) Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 42: 1333–1339.
24. de Wolf F, Spijkermer I, Schellekens PT, Langendam M, Kuiken C, et al. (1997) AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 11: 1799–1806.
25. Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, et al. (1996) Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcomes. AIDS 10: 167–173.
26. Kelley CF, Barbou JD, Hecht FM (2007) The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 45: 445–448.
27. Mahnke YD, Song K, Sauer MM, Nason MC, Giret MT, et al. (2013) Early immunologic and virologic predictors of clinical HIV-1 disease progression. AIDS 27: 697–706.
28. Kauffman GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, et al. (2000) Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 14: 2643–2651.
29. Dorracci M, Rezza G, Porter K, Phillips A (2007) Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1983–2002. J Infect Dis 195: 532–534.
30. Cram-Gianfilese NF, Ren Q, Eberly LE, Ganesan A, Weinrob A, et al. (2010) Are HIV-positive persons progressing faster after diagnosis over the epidemic? J Acquir Immune Defic Syndr 54: e6–7.
31. Fuller S, Porter K, Evings F, Frater J, Ramjee G, et al. (2013) Short-course antiretroviral therapy in primary HIV-1 infection. N Engl J Med 368: 207–217.
32. Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, et al. (2012) The impact of antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 205: 87–96.
33. Grijzen ML, Steingover R, Wit FW, Jurriaans S, Verbon A, et al. (2012) No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHIM trial. PLoS Med 9: e1001196.
34. Hamlyn E, the SPARTAC Trial Investigators (2011) The effect of short-course ART initiated in primary HIV-1 infection on IL-6 and Dillmore: results from SPARTAG, and international randomised controlled trial: 2011 October 2011; Belgrade.